Innate Pharma SA said that it has sufficient cash to finance its clinical programmes into 2011 even as it steps up development of its candidate products for cancer. A Phase 2a trial of a monoclonal antibody for multiple myeloma is set to start soon.
Ablynx NV nearly doubled its revenues to €11.9 million in the first half of 2009 following milestone payments from its research collaborators, Novartis, Wyeth, Boehringer Ingelheim and Merck Serono.
The UK specialty pharmaceutical company, ProStrakan Group Plc, is to receive $10 million upfront in an exclusive licensing and distribution deal with Endo Pharmaceuticals Inc for its testosterone replacement therapy, Fortesta.
Ark Therapeutics Group Plc said that it expects a regulatory decision on its application to market a novel gene therapy in Europe for patients with malignant glioma, a type of brain cancer, by the end of 2009.
Intercell AG reported revenue of €14.9 million in the second quarter of 2009, helped by the launch of its first product, a vaccine to protect against Japanese Encephalitis, on markets in Europe, the US and Australia.
Crucell NV expects that revenue and other operating income will increase by 20% in 2009, confirming that it does not expect to be materially affected by the global recession.
Evotec AG has raised its revenue guidance for 2009 following the strong performance of its drug discovery business in the second quarter. Revenue for the year is now expected to be more than 40 million euros.
MediGene AG reported an increase in revenue in the first half of 2009, mainly generated from the commercialisation in Europe of its treatment for prostate cancer, Eligard.
Galapagos NV expects to report revenue of 100 million euros in 2009, up by 30% from a year earlier on growth in income from its risk-sharing alliances with Big Pharma and from its service division.
BioAlliance Pharma SA plans to break into the US market with a treatment for patients who are susceptible to opportunistic infections because their immune systems have been compromised.